{"id":44307,"date":"2022-05-25T00:01:28","date_gmt":"2022-05-24T22:01:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/asc-therapeutics-joins-u-s-consortium-of-gene-therapy-partners-including-the-nih-and-fda-to-accelerate-treatments-for-rare-diseases\/"},"modified":"2022-05-25T00:01:28","modified_gmt":"2022-05-24T22:01:28","slug":"asc-therapeutics-joins-u-s-consortium-of-gene-therapy-partners-including-the-nih-and-fda-to-accelerate-treatments-for-rare-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/asc-therapeutics-joins-u-s-consortium-of-gene-therapy-partners-including-the-nih-and-fda-to-accelerate-treatments-for-rare-diseases\/","title":{"rendered":"ASC Therapeutics Joins U.S. Consortium of Gene Therapy Partners Including the NIH and FDA to Accelerate Treatments for Rare Diseases"},"content":{"rendered":"
\n

\nPublic, private and non-profit organizations have joined forces to create a standardized approach that will reduce up-front costs and lower barriers to developing novel gene therapies for rare and ultra-rare diseases\n<\/p>\n

<\/a><\/p>\n

MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies has joined as a full partner the Accelerating Medicines Partnership\u00ae Bespoke Gene Therapy Consortium (AMP\u00ae BGTC) including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), managed by the Foundation for the National Institutes of Health (FNIH)<\/a>.\n<\/p>\n

\nThe AMP\u00ae BGTC brings together partners from the public, private, and non-profit sectors<\/a> to foster development of gene therapies intended to treat rare genetic diseases, which affect populations too small for viable commercial development. BGTC has defined the following objectives:\n<\/p>\n